申请人:Goedecke Aktiengesellschaft
公开号:US05037987A1
公开(公告)日:1991-08-06
The present invention provides a process for the separation of the naphthyridine derivatives (.+-.)-1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-n aphthyridine-3-carboxylic acid ethyl ester and (.+-.)-1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-n aphthyridine-3-carboxylic acid [2-(N-methyl-N-phenylmethylamino)ethyl] ester into the optical antipodes by use of the (.+-.)-1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-n aphthyridine-3-carboxylic acid benzyl ester and optically-active O,O'-dibenzoyltartaric acid. Said optical antipodes are calcium antagonists useful in the treatment of blood vessel diseases.
本发明提供了一种分离萘啶衍生物(.+-.)-1,4-二氢-5-异丙氧基-2-甲基-4-(2-三氟甲基苯基)-1,6-萘啶-3-羧酸乙酯和(.+-.)-1,4-二氢-5-异丙氧基-2-甲基-4-(2-三氟甲基苯基)-1,6-萘啶-3-羧酸[2-(N-甲基-N-苯甲基氨基)乙基]酯的过程,通过使用(.+-.)-1,4-二氢-5-异丙氧基-2-甲基-4-(2-三氟甲基苯基)-1,6-萘啶-3-羧酸苄酯和光学活性的O,O'-二苯甲酰酒石酸将其分离成光学对映体。所述光学对映体是治疗血管疾病有用的钙拮抗剂。